203 related articles for article (PubMed ID: 6347202)
1. Effects of PGI2 on platelet aggregation and adenylate cyclase activity in human type IIa hypercholesterolemia.
Colli S; Lombroso M; Maderna P; Tremoli E; Nicosia S
Biochem Pharmacol; 1983 Jul; 32(13):1989-93. PubMed ID: 6347202
[TBL] [Abstract][Full Text] [Related]
2. Prostacyclin-lipoprotein interactions. Studies on human platelet aggregation and adenylate cyclase.
Colli S; Maderna P; Tremoli E; Baraldi A; Rovati GE; Gianfranceschi G; Nicosia S
Biochem Pharmacol; 1985 Jul; 34(14):2451-7. PubMed ID: 3893439
[TBL] [Abstract][Full Text] [Related]
3. Epoprostenol (prostacyclin, PGI2) binding and activation of adenylate cyclase in platelets of diabetic and control subjects.
Shepherd GL; Lewis PJ; Blair IA; de Mey C; MacDermot J
Br J Clin Pharmacol; 1983 Jan; 15(1):77-81. PubMed ID: 6342639
[TBL] [Abstract][Full Text] [Related]
4. Effects of heparin on prostacyclin binding and platelet adenylate cyclase activity stimulated by iloprost and forskolin.
Jaschonek K; Faul C; Daiss W; Weisenberger H
Prostaglandins Leukot Med; 1986 Oct; 24(2-3):199-206. PubMed ID: 2432618
[TBL] [Abstract][Full Text] [Related]
5. Desensitization of prostaglandin-activated platelet adenylate cyclase.
Cooper B; Schafer AI; Puchalsky D; Handin RI
Prostaglandins; 1979 Apr; 17(4):561-71. PubMed ID: 461820
[TBL] [Abstract][Full Text] [Related]
6. The use of stable prostaglandins to investigate prostacyclin (PGI2)-binding sites and PGI2-sensitive adenylate cyclase in human platelet membranes.
Lombroso M; Nicosia S; Paoletti R; Whittle BJ; Moncada S; Vane JR
Prostaglandins; 1984 Feb; 27(2):321-33. PubMed ID: 6326201
[TBL] [Abstract][Full Text] [Related]
7. Simvastatin reduces platelet thromboxane formation and restores normal platelet sensitivity against prostacyclin in type IIa hypercholesterolemia.
Schrör K; Löbel P; Steinhagen-Thiessen E
Eicosanoids; 1989; 2(1):39-45. PubMed ID: 2483819
[TBL] [Abstract][Full Text] [Related]
8. (5Z)-carbacyclin discriminates between prostacyclin-receptors coupled to adenylate cyclase in vascular smooth muscle and platelets.
Corsini A; Folco GC; Fumagalli R; Nicosia S; Noe MA; Oliva D
Br J Pharmacol; 1987 Jan; 90(1):255-61. PubMed ID: 3545351
[TBL] [Abstract][Full Text] [Related]
9. Diminished platelet adenylate cyclase activation by prostaglandin D2 in acute thrombosis.
Cooper B
Blood; 1979 Sep; 54(3):684-93. PubMed ID: 380688
[TBL] [Abstract][Full Text] [Related]
10. Differential requirements for platelet aggregation and inhibition of adenylate cyclase by epinephrine. Studies of a familial platelet alpha 2-adrenergic receptor defect.
Rao AK; Willis J; Kowalska MA; Wachtfogel YT; Colman RW
Blood; 1988 Feb; 71(2):494-501. PubMed ID: 2827817
[TBL] [Abstract][Full Text] [Related]
11. Prostaglandin endoperoxide analogues which are both thromboxane receptor antagonists and prostacyclin mimetics.
Armstrong RA; Jones RL; MacDermot J; Wilson NH
Br J Pharmacol; 1986 Mar; 87(3):543-51. PubMed ID: 3026540
[TBL] [Abstract][Full Text] [Related]
12. Effects of TRK-100, a stable prostacyclin analogue, on regulation of cyclic AMP metabolism in platelets.
Nogimori K; Kajikawa N; Nishio S; Yajima M
Prostaglandins; 1989 Feb; 37(2):205-12. PubMed ID: 2543034
[TBL] [Abstract][Full Text] [Related]
13. Refractoriness of platelets to prostaglandins after infusion in rabbits.
Bertelé V; Stemerman M; Schafer A; Adelman B; Smith M; Fuhro R; Salzman E
J Lab Clin Med; 1985 Nov; 106(5):551-61. PubMed ID: 2997353
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of platelet aggregation by prostacyclin is attenuated after exercise in patients with angina pectoris.
Kishi Y; Ashikaga T; Numano F
Am Heart J; 1992 Feb; 123(2):291-7. PubMed ID: 1736562
[TBL] [Abstract][Full Text] [Related]
15. Cytochemical localization of adenylate cyclase in the dense tubule system of human blood platelets stimulated by forskolin, prostacyclin and prostaglandin D2.
Cutler LS; Christian CP; Feinstein MB
Biochim Biophys Acta; 1985 Jun; 845(3):403-10. PubMed ID: 3890960
[TBL] [Abstract][Full Text] [Related]
16. Prostacyclin inhibits mobilisation of fibrinogen-binding sites on human ADP- and thrombin-treated platelets.
Hawiger J; Parkinson S; Timmons S
Nature; 1980 Jan; 283(5743):195-7. PubMed ID: 6985716
[TBL] [Abstract][Full Text] [Related]
17. Adenosine 5-diphosphate antagonists and human platelets: no evidence that aggregation and inhibition of stimulated adenylate cyclase are mediated by different receptors.
Cusack NJ; Hourani SM
Br J Pharmacol; 1982 May; 76(1):221-7. PubMed ID: 6282375
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of adenylate cyclase by adenosine analogues in preparations of broken and intact human platelets. Evidence for the unidirectional control of platelet function by cyclic AMP.
Haslam RJ; Davidson MM; Desjardins JV
Biochem J; 1978 Oct; 176(1):83-95. PubMed ID: 215136
[TBL] [Abstract][Full Text] [Related]
19. Influence of type IIa, IIb and IV-hyperlipoproteinemia on platelet prostaglandin sensitivity, plasma thromboxane B2 and platelet half-life.
Strobl-Jäger E; Widhalm K; Sinzinger H
Prostaglandins Leukot Med; 1986 Nov; 25(1):39-47. PubMed ID: 3540998
[TBL] [Abstract][Full Text] [Related]
20. Studies on antiplatelet effects of OP-41483, a prostaglandin I2 analog, in experimental animals. II. Mechanism of its antiplatelet effect.
Fujitani B; Wakitani K
Jpn J Pharmacol; 1990 May; 53(1):25-33. PubMed ID: 2161965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
